Laboratory production of T cells-immune cells that grow naturally in the thymus gland-could provide new therapies against cancer, autoimmune disorders and organ transplant rejection. But they’re hard to grow in culture dishes; current methods yield too few cells of too little variety. Researchers from Massachusetts General Hospital in Boston and the Woburn, MA, biotechnology firm Cell Science Therapeutics have developed an artificial thymus that solves both problems. Constructed from a porous metal-and-carbon material typically used for bone repair and arranged in a three-dimensional matrix, the structure mimics the functions of a living-tissue thymus, generating a bumper crop of T cells that can adjust to new threats. Clinical trials start in 2002, with commercial availability expected a few years later. -M. Wortman
Geoffrey Hinton tells us why he’s now scared of the tech he helped build
“I have suddenly switched my views on whether these things are going to be more intelligent than us.”
Meet the people who use Notion to plan their whole lives
The workplace tool’s appeal extends far beyond organizing work projects. Many users find it’s just as useful for managing their free time.
Learning to code isn’t enough
Historically, learn-to-code efforts have provided opportunities for the few, but new efforts are aiming to be inclusive.
Deep learning pioneer Geoffrey Hinton has quit Google
Hinton will be speaking at EmTech Digital on Wednesday.
Get the latest updates from
MIT Technology Review
Discover special offers, top stories, upcoming events, and more.